CNBX - Cannabics Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.03
0.00 (0.00%)
At close: 3:57PM EST
Stock chart is not supported by your current browser
Previous Close1.03
Open1.03
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.03 - 1.08
52 Week Range0.44 - 7.60
Volume165,613
Avg. Volume307,633
Market Cap123.152M
Beta-6.58
PE Ratio (TTM)N/A
EPS (TTM)-0.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cannabics Pharmaceuticals, Inc. :CNBX-US: Earnings Analysis: Q4, 2017 By the Numbers : December 11, 2017
    Capital Cube6 days ago

    Cannabics Pharmaceuticals, Inc. :CNBX-US: Earnings Analysis: Q4, 2017 By the Numbers : December 11, 2017

    Categories: Yahoo FinanceGet free summary analysis Cannabics Pharmaceuticals, Inc. reports financial results for the quarter ended August 31, 2017. We analyze the earnings along side the following peers of Cannabics Pharmaceuticals, Inc. – Fibrocell Science, Inc., Ignyta, Inc., Fate Therapeutics, Inc., Chimerix, Inc. and Acorda Therapeutics, Inc. (FCSC-US, RXDX-US, FATE-US, CMRX-US and ACOR-US) that have also reported ... Read more (Read more...)

  • PR Newswire19 days ago

    Cannabics Pharmaceuticals Received a New Research License for Characterization of Anti-Tumor Activity of Cannabinoids

    TEL-AVIV, Israel, Nov. 28, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has received a new research license from the Israeli Ministry of Health for the Characterization of anti-tumor activity of cannabinoids. The new license will enable the company to continue our vision of developing an ecosystem for creation of diagnostic tools and bringing to the market diagnostic services for cancer patients who are medicated with cannabis.

  • PR Newswirelast month

    Cannabics Pharmaceuticals Files Patent Application on Cannabinoid Modulation of the Microbiome

    Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed the first of a cluster of patent applications with the US Patent & Trademark Office (USPTO) which covers their ongoing work on the use of cannabinoid products for adjusting the varied microbial populations that live on and in the body. The pioneering work based on profiling and modulating patient-derived microbiota, personalizes and profiles individual health status. This will make possible the optimization of pharmacological treatments for patients.

  • Cannabics Pharmaceuticals Files National Phase Applications for Its System and Method for High Throughput Screening of Cancer Cells
    PR Newswire3 months ago

    Cannabics Pharmaceuticals Files National Phase Applications for Its System and Method for High Throughput Screening of Cancer Cells

    TEL AVIV, Israel, September 25, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) today announced it has filed national phase patent applications for its 'System and Method for High Throughput Screening of Cancer Cells' in the United States, Europe, China, India, Brazil, Canada and Australia. The company has filed the national phase applications after having received a favorable international patentability report from the PCT authorities regarding patent application PCT/IL2016/050471 finding all the claims innovative and inventive. The proprietary technology patented relates to novel means of personalizing cannabis based treatments of cancer utilizing high throughput screening of biopsies and cell lines treated with pure or crude extracts.

  • PR Newswire3 months ago

    Cannabics Pharmaceuticals Files a Patent Application for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs

    Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed an extensive provisional patent application with the US Patent & Trademark Office (USPTO) on a new Method for Sensitivity Tests of Cannabinoids on Patient-Derived Tumor Biopsies and CTCs. The method, developed by Cannabics Pharmaceuticals, expands the company's proprietary technology of personalization of cannabinoid medicine.

  • Cannabics Pharmaceuticals Received Positive Report from The Patent Cooperation Treaty Regarding Cannabinoid Personalized Screening of Cancer Cells
    PR Newswire4 months ago

    Cannabics Pharmaceuticals Received Positive Report from The Patent Cooperation Treaty Regarding Cannabinoid Personalized Screening of Cancer Cells

    TEL-AVIV, Israel, August 28, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) (CNBX) today announced it received a very positive preliminary international patentability report from the PCT authorities regarding patent application PCT/IL2016/050471 finding all claims innovative and inventive. This PCT report is a major step in the progress of the patent application which is now being launched into several major countries and territories. The company is securing its achievements through a very active and expanding patent portfolio.

  • PR Newswire5 months ago

    Cannabics Pharmaceuticals Establishes a Human-Cannabis-Cancer Genetics lab to Expand its Personalized Diagnostics

    Cannabics Pharmaceuticals Inc. (OTC-QB: CNBX) today announced it has established a Genetic lab that will develop diagnostic tools based on human genome, tumor genetics and cannabinoids. The company recruited Dr. Moran Grinberg to serve as its VP of R&D and to lead the Genetic research. Moran has a PhD in Virology and MSc in clinical pharmacology with vast experience in conceptualizing and executing pharmacological research.

  • PR Newswire5 months ago

    Cannabics Pharmaceuticals Executed a Final Collaboration Agreement with SIMFO GmbH

    Cannabics Pharmaceuticals Inc. (CNBX) today announced it has executed a Collaboration Agreement with SIMFO GmbH, a world leader in cancer diagnostics and liquid biopsies located in Germany. Under the Agreement, Cannabics Pharmaceuticals shall be the exclusive global provider of SIMFO's CTC diagnostics to cancer patients treated with natural cannabinoids. The diagnostics include a count of circulating tumor cells (CTC) and drug sensitivity tests of different cannabinoids (e.g.

  • PR Newswire6 months ago

    Cannabics Pharmaceuticals Receives Positive Results in Drug Sensitivity Tests on CTCs

    Cannabics Pharmaceuticals Inc. (CNBX) today announced it received positive results from screening necrosis (cell death) of circulating tumor cells, from cancer patients, treated with the cannabinoids CBD and CBDA. In addition, the screening results which indicate varied effectiveness of the tested cannabinoids upon different tumors (colon, breast, prostate) reaffirm the use of our proprietary technology in providing supportive data for personalized treatments. Dr. Eyal Ballan, CTO of Cannabics Pharmaceuticals noted "The screening of CTCs treated with specific cannabinoids and CTC cell count of patients treated with cannabinoids produces an invaluable body of data in our search for effective anti-tumor treatment".

  • PR Newswire7 months ago

    Cannabics Pharmaceuticals Inc. Provides Shareholders Update June 2017

    Cannabis has the potential of being a natural cancer attenuator comprising numerous active compounds which interact with human cells in a complex manner. Understanding the biological mechanism is a long and profound process, yet, utilizing diagnostic lab tests and clinical studies this potential can be unraveled. Cannabics Pharmaceuticals engages in various technologies and studies that together create the knowledge of treating cancer patients with cannabis.

  • PR Newswire7 months ago

    Cannabics Pharmaceuticals Inc. Provides Shareholders Update June 2107

    Cannabis has the potential of being a natural cancer attenuator comprising numerous active compounds which interact with human cells in a complex manner. Understanding the biological mechanism is a long and profound process, yet, utilizing diagnostic lab tests and clinical studies this potential can be unraveled. Cannabics Pharmaceuticals engages in various technologies and studies that together create the knowledge of treating cancer patients with cannabis.

  • PR Newswire7 months ago

    Cannabics Pharmaceuticals Raises $3,000,000 in Capital Raise Transaction

    Cannabics Pharmaceuticals Inc. (CNBX) today announced it has entered into a securities purchase agreement with D-Beta One EQ, Ltd. ("D-Beta"). D-Beta will purchase 3,000,000 shares of common stock (the "Purchased Shares") at a purchase price of $1.00 per share, for aggregate proceeds of $3.0 million and may purchase up to an additional 1,500,000 shares of common stock (the "Additional Shares") at a purchase price of $2.00 per share over the next 12 months. Pursuant to the Purchase Agreement, Cannabics Pharmaceuticals is required to register all shares previously acquired by D-Beta or its affiliates, the Purchased Shares, and the Additional Shares.

  • Cannabics Pharmaceuticals Announces Scientific Collaboration With A Leading CTC European Lab
    PR Newswire7 months ago

    Cannabics Pharmaceuticals Announces Scientific Collaboration With A Leading CTC European Lab

    TEL AVIV, Israel, May 3, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) today announced it has begun a scientific collaboration with a medical laboratory in Europe, a world leader in the field of CTC (circulating tumor cells) count and drug sensitivity tests for cancer patients. The blood test results enables practitioners and patients to monitor the number of circulating tumor cells as an indication for cancer characteristics, treatment efficacy and and re-occurrence.

  • Forbes8 months ago

    Here Are The 5 Stocks Added To The U.S. Marijuana Index

    The United States Marijuana Index has jumped from a level of 48.39 a year ago to the current level of 70.83, an increase of 46%.

  • Cannabics Pharmaceuticals Inc. Receives the Final Report of Its Research on Antitumor Properties of Cannabinoids Held in Israel
    PR Newswire8 months ago

    Cannabics Pharmaceuticals Inc. Receives the Final Report of Its Research on Antitumor Properties of Cannabinoids Held in Israel

    TEL AVIV, Israel, April 3, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) is pleased to announce that it received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer (breast, ovarian, colon, pancreatic, gastric, glioblastoma). The results which were obtained, using High Throughput Screening technology (HTS), clearly indicate that the company's cannabinoid compounds caused apoptosis (programed cancer cell death) in all cancer types mentioned above with no effect on healthy normal cells. Itamar Borochov, CEO of Cannabics Pharmaceuticals said, "The results from this research strengthen our vision of creating anticancer treatments based on natural cannabis medicine".

  • PR Newswire9 months ago

    Cannabics Pharmaceuticals Inc. Receives the Final Report of Its Research on Antitumor Properties of Cannabinoids Held in Israel

    TEL AVIV, Israel, April 3, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) is pleased to announce that it received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer (breast, ovarian, colon, pancreatic, gastric, glioblastoma). The results which were obtained, using High Throughput Screening technology (HTS), clearly indicate that the company's cannabinoid compounds caused apoptosis (programed cancer cell death) in all cancer types mentioned above with no effect on healthy normal cells. Itamar Borochov, CEO of Cannabics Pharmaceuticals said, "The results from this research strengthen our vision of creating anticancer treatments based on natural cannabis medicine".

  • Benzinga9 months ago

    Cronos Execs On Marijuana Legalization In Canada And How It Affects The Co: Market Could Be Ready To Go By 2019

    In a recent chat with Cronos Group Inc (CVE: MJN) (OTC: PRMCF )’s President and CEO Michael Gorenstein, and its head of marketing and communications, Eric Klein, we looked into the challenges of exporting ...

  • PR Newswire9 months ago

    Cannabics Pharmaceuticals Inc. Appoints New Members to its Board of Advisors

    TEL AVIV, Israel, March 9, 2017 /PRNewswire/ -- Cannabics' Pharmaceutical (CNBX) Board of Directors is proud to announce its addition of several highly-respected professionals to its Board of Advisors. ...

  • Accesswire10 months ago

    This Thirty Cent Hair Loss and Skin Care Stock Could Outperform ALL Marijuana Stocks

    NEW YORK, NY / ACCESSWIRE / March 02, 2017 / Marijuana stocks are hot. It's wrong, though, to think that all marijuana stocks are performing well. They're not. There are plenty of examples of marijuana ...

  • PR Newswire10 months ago

    Cannabics Pharmaceuticals Inc. Provides Shareholders Update Regarding Increased Volume in its Shares

    BETHESDA, Maryland, Feb. 23, 2017 /PRNewswire/ -- The management of Cannabics Pharmaceuticals Inc. (CNBX) wishes to inform its shareholders and public at large that is acutely aware of the significant increase in its share volume this past month and was contacted by OTC Markets on February 21st regarding this matter. Itamar Borochov, CEO of Cannabics Pharmaceuticals, says "We are very aware of the increased interest in our science and its apparent results in the marketplace." I wish to reiterate that there is neither any undisclosed material information available nor any paid promotional activity or Investor Relations for the Company at all. The sole source of the Company's public information has been press releases which we, the Company, authorize and release ourselves and may be found under "News" on OTC Markets site or on our Website (www.Cannabics.com).

  • Accesswire10 months ago

    Cannabics Pharmaceuticals, Inc. Breakthrough Cannabis Medications Review and Outlook

    NEW YORK, NY / ACCESSWIRE / February 21, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies, is covering Cannabics ...

  • PR Newswire10 months ago

    Cannabics Pharmaceuticals Announces Initial Commercialization of Cannabinoids-based Personalized Diagnostics for Cancer Patients

    BETHESDA, Maryland, Feb. 6, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) today announced it will begin providing personalized cannabinoid anti-tumor tests for cancer patients. The diagnostic tests are based on liquid biopsies of patients suffering from any kind of cancer. The test uses CTC technology that collects cancer cells from patients' blood samples, and tests their sensitivity to cannabinoid compounds alongside conventional chemotherapy medicine.

  • PR Newswire11 months ago

    Cannabics Pharmaceuticals Announces a New Dosage of 5mg THC Cannabis Capsule Treating Cancer Patients Suffering from Cachexia and Anorexia Syndrome

    BETHESDA, Maryland, Jan. 3, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) today announced development of Cannabics 5mg THC Capsule intended for naïve patient who have not tried cannabis in the past. The Cannabics 5mg THC capsule is currently being evaluated by the company in a clinical study as a palliative treatment, which is conducted by the oncology department at the prestigious Rambam Medical Center in northern Israel and under strict regulations of the Ministry of Health, by whom Cannabics Pharmaceuticals has been licensed since 2014.